Drug Trial Radar · NCT04725474
First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)
Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
199
Actual
Start
Dec 9, 2020
Primary completion
Apr 30, 2028
Study completion Apr 30, 2030
Sponsor
- Lead sponsor
- CatalYm GmbHIndustry
- Sponsor type
- Industry
- First posted
- Jan 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Phase 1 part (Part A) is a dose escalation study of IV visugromab (CTL-002, a monoclonal antibody neutralizing GDF-15) as monotherapy and in combination with an approved checkpoint inhibitor (CPI) in patients with advanced solid tumors. Enrolment into the Ph 1 part is completed. The Phase 2 parts (Part B) are cohort expansions with visugromab (CTL-002) in combination with a defined CPI at a fixed dose into seven different solid tumor indications. Enrolment into the Ph 2 part is completed.
Conditions
- Solid Tumor, Adult
Interventions
visugromab (CTL-002)Biological
monoclonal antibody
nivolumabBiological
monoclonal antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Events (Parts A & B)Time frame: min. 2 months
- Determination of DLT and MTD (Part A)Time frame: 28 days
- Evaluation of clinical efficacy according RECIST V1.1 (Part B)Time frame: min. 6 weeks
Locations
13 sites in 3 countries. Site status is shown where the registry gives one.
Universitätsklinikum Essen, Westdeutsches Tumorzentrum, Innere Klinik und Poliklinik
Essen, Germany
Universitätsklinikum Frankfurt, Medizinische Klinik I
Frankfurt am Main, Germany
Universitätsklinikum Würzburg, Comprehensive Cancer Center
Würzburg, Germany
Next Oncology, Phase I Unit. IOB - Hospital Quironsalud
Barcelona, Spain
Hospital Universitari Vall d'Hebron, Institute of Oncology
Barcelona, Spain
ICMDiM, Hospital Clinic
Barcelona, Spain
ICO Hospitalet, Hospital Duran i Reynals
Barcelona, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
START Madrid, Hospital Universitario HM Sanchinarro
Madrid, Spain
Clinica Universidad de Navarra, Unidad Central de Ensayos Clinicos
Pamplona, Spain
University Hospital Basel, Department for Medical Oncology
Basel, Switzerland
Kantonsspital St. Gallen, Clinic for Medical Oncology & Hematology
Sankt Gallen, Switzerland
University Hospital Zurich, Department of Dermatology
Zurich, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.